Inclusion Criteria:  Patients ages 18 to 65 years old at the time of enrollment. Patients weighing at least 42 kg Patient with the hematologic malignancies described below, as well as an HLA matched related donor, HLA matched unrelated donor, a haploidentical related donor, or a one antigen mismatched unrelated donor. HLA matching includes HLA A, B, C, and DR-B1. Patients must have one of the following diseases:  Acute myeloid leukemia (AML):  a. First complete remission with high-risk features defined as: (i) Greater than 1 cycle of induction therapy required to achieve remission; (ii) Preceding myelodysplastic syndrome (MDS); Presence of FLT3 mutations or internal tandem duplication or other mutations designated as adverse-risk by the ELN criteria  Adverse:  t(6;9)(p23;q34.1); DEK-NUP214 t(v;11q23.3); KMT2A rearranged t(9;22)(q34.1;q11.2); BCR-ABL1 inv(3)(q21.3q26.2) or t(3;3)(q21.3;q26.2); GATA2,MECOM(EVI1) -5 or del(5q); -7; -17/abn(17p) Complex karyotype, monosomal karyotype Wild-type NPM1 and FLT3-ITDhigh Mutated RUNX1 Mutated ASXL1  Mutated TP53 (iv) FAB M6 or M7 classification; (v) Adverse cytogenetics: -5, del 5q, -7, del7q, abnormalities involving 3q, 9q, 11q, 20q, 21q, 17, +8 or complex karyotype [> 3 abnormalities]; or other mutations designated as adverse-risk by the ELN criteria; (vi) Treatment-related AML (vii) Primary induction failure with partial response to therapy who achieve adequate cytoreduction, or (viii) Aplastic/hypoplastic marrow with or without detectable persistent disease after induction chemotherapy or after salvage chemotherapy.  b. Patients must be in (i) CR: complete remission, (ii) CRi: CR with incomplete hematologic recovery, or (iii) MLFS: morphological leukemia-free state with less than 5% bone marrow blasts.  Patients cannot be beyond CR3, i.e., have relapsed more than 2 times.  Myelodysplastic syndromes (MDS):  a. De novo MDS with intermediate or high-risk IPSS scores. Patients with intermediate-1 features should have failed to respond to hypomethylating agent therapy, or patients with treatment-related MDS.  Patients must have less than 10% bone marrow blasts  Chronic myeloid leukemia (CML):  Failed to achieve cytogenetic remission or have cytogenetic relapse after treatment with at least 2 tyrosine kinase inhibitors, or Accelerated phase or blast phase at any time.  Intolerant of available TKIs  Performance score of at least 70% by Karnofsky or 0 to 1 by ECOG.  Adequate major non-hematopoietic organ system function as demonstrated by:  Serum creatinine clearance equal or more than 50 ml/min (calculated with Cockroft-Gault formula). Bilirubin equal or less than 1.5 mg/dl except for Gilbert's disease. ALT or AST equal or less than 200 IU/ml for adults. Conjugated (direct) bilirubin less than 2x upper limit of normal. Left ventricular ejection fraction equal or greater than 45%.  Diffusing capacity for carbon monoxide (DLCO) equal or greater than 60% predicted corrected for hemoglobin.  Ability to understand and willingness to sign the written informed consent document. Sexually active males and females of childbearing potential must agree to use a form of contraception considered effective and medically acceptable by the Investigator while on study.  Exclusion Criteria:  HIV positive; active hepatitis B or C. Uncontrolled infections; PI is the final arbiter of this criterion. Liver cirrhosis. CNS involvement within 3 months prior to the transplant. Positive pregnancy test in a woman with child bearing potential defined as not post-menopausal for 12 months or no previous surgical sterilization. Inability to comply with medical therapy or follow-up. Patient with a known history of allergic reactions to any constituents of the product, including a known history of allergic reactions to cellular products or DMSO. Prior allogeneic SCT Other malignancy/cancer diagnosis <2 years ago, not including nonmelanoma skin cancer Requiring systemic corticosteroids with prednisone dose >10 mg or equivalent. KDS-1001 Donor specific antibodies (dsa) >5000 MFI units KDS-1001 Donor anti-C1q positive